New Mucon Series K2P Powered Iris Valve Technology - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

New Mucon Series K2P Powered Iris Valve Technology

Mucon a division of Process Components Ltd has launched its new Series K2P electrically / pneumatically actuated range of Iris valves. The Mucon brand of Iris diaphragm valves has for over sixty years been associated with the control of powders, granules, capsules and pellets to the Pharmaceutical, Chemical and Food processing sectors.
Now in its second generation, the Series K2 Powered Iris Valves have been specifically designed for automatic and remote applications, complimenting the popular hand operated versions.

Developed for applications requiring a high level of hygiene, this valve utilises our patented, moulded diaphragm technology already employed throughout the K-Valve range.

Mucon Engineers have taken great care to balance customer requirements for quick disconnect, ease of cleaning and hygienic design with the requirements for reliability and control system integration.

All body parts are manufactured from 316 stainless steel, as standard. White moulded diaphragms of Natural Rubber, EPDM and Silicone are all manufactured from FDA approved materials.

The salient features and benefits of the new MUCON K2P valve are as follows;

  • Extensively used in the Pharmaceutical, Chemical and Food sectors
  • FDA approved diaphragm materials
  • Full product flow control
  • Non-Jamming
  • No mechanical parts in contact with the product
  • Slim Design
  • Electric and Pneumatic actuation
  • ATEX approved Cat. 1D / 2D
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
FindPharma Custom Search

Click here